ANI Pharmaceuticals Company Insiders

ANI Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.0237 % which means that it generated a profit of $0.0237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0866 %, meaning that it created $0.0866 on every $100 dollars invested by stockholders. ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/09/2026, Return On Capital Employed is likely to grow to 0.0005, while Return On Tangible Assets are likely to drop (0.03). At this time, ANI Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 02/09/2026, Liabilities And Stockholders Equity is likely to grow to about 1.6 B, while Non Current Liabilities Other is likely to drop slightly above 16.1 M. As of 02/09/2026, Common Stock Shares Outstanding is likely to grow to about 23.3 M, though Net Loss is likely to grow to (42.3 M). ANI Pharmaceuticals holds a total of 22.46 Million outstanding shares. The majority of ANI Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ANI Pharmaceuticals to benefit from reduced commissions. Thus, institutional investors are subject to a different set of regulations than regular investors in ANI Pharmaceuticals. Please pay attention to any change in the institutional holdings of ANI Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that nearly one million three hundred fourty-five thousand two hundred fourty-four invesors are currently shorting ANI Pharmaceuticals expressing very little confidence in its future performance. At this time, ANI Pharmaceuticals' Dividends Paid is relatively stable compared to the past year. As of 02/09/2026, Dividend Paid And Capex Coverage Ratio is likely to grow to 3.26, while Dividend Yield is likely to drop 0. As of 02/09/2026, Common Stock Shares Outstanding is likely to grow to about 23.3 M, though Net Loss is likely to grow to (42.3 M).

ANI Pharmaceuticals Workforce Comparison

The company has Profit Margin (PM) of 0.05 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.1 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.1.

ANI Pharmaceuticals Insider Trading History

ANI Pharmaceuticals Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as ANI Pharmaceuticals often depends on how effective the management is. ANI Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ANI management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ANI management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.